Business
Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad
About this update from Denali Therapeutics Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2019, and provided business highlights.\n “Our clinical and preclinical programs continue to progress and we plan to submit an IND or CTA for two programs by year-end 2019. One of these programs, ETV:IDS, will be our first biotherapeutic engineered to cross the blood-brain barrier using our Transport Vehicle platform. We are also particularly excited about our LRRK2 program and the potential to make a difference for patients suffering from Parkinson's disease,” said Ryan Watts, Ph.D., CEO. Third Quarter 2019 and Recent Business Highlights First patient dosed in DNL151 Phase 1b clinical trial - In September 2019, Denali announced initiation of dosing in a Phase 1b clinical study of LRRK2 inhibitor DNL151 in patients with Parkinson's disease, and the launch of its Engage Parkinson's website. RIPK1 program update - The DNL747 Phase 1b trials in Alzheimer's disease and ALS continue to progress, enrollment of an ALS open label extension in the Netherlands has commenced, and sites for the Phase 1b ALS study have been expanded into the United States. Denali intends, together with its partner Sanofi, to evaluate the full data set from the ongoing clinical and preclinical studies to inform decisions on further clinical testing for the RIPK1 program. The timing of such decisions is delayed to mid-2020. First patient enrolled in Hunter Syndrome patient biomarker study - In October 2019, Denali enrolled the first patient in a biomarker study for the ETV:IDS program in Hunter Syndrome. This non-interventional study is expected to yield critical biomarker and clinical data in patients to inform future clinical studies with DNL310 (ETV:IDS) and facilitate patient recruitment into these studies. DNL310 is a CNS-penetrant, intravenous enzyme replacement therapy that utilizes our Transport Vehicle platform technology to increase penetration across the blood-brain barrier. Leadership promotions - In November 2019, Zach Sweeney was promoted to Chief Scientific Officer, and Cindy Dunkle was promoted to Chief People Officer. Both Zach and Cindy joined Denali in 2015...